NEW YORK (GenomeWeb News) – Trovagene today announced it has granted Duke University and Duke University Health Systems a non-exclusive license covering the use of the nucleophosmin protein (NPM1).

The agreement allows Duke to incorporate NPM1 into research and clinical testing services for acute myelogenous leukemia. The terms of the deal includes upfront payments and royalties. Further details were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.